ALK 的研发

过敏研究先锋

了解过敏

ALK 对过敏原及其对人体的影响的认识无与伦比，对过敏症与呼吸道疾病（如哮喘）之间的关系亦有透彻的了解。

Video of understanding_allergy

See all

Post date
04/23/2025
ITULAZAX® tree pollen tablet approved for treatment of children in Europe
Read more
Post date
04/03/2025
Grant of share-based long-term incentive instruments to members of the Board of Management and key employees
Read more
Post date
03/13/2025
Annual General Meeting in ALK-Abelló A/S held on 13 March 2025
Read more
Post date
03/07/2025
ACARIZAX® approved in Canada for treatment of young children
Read more
Post date
03/04/2025
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Read more
Post date
02/27/2025
FDA approves ODACTRA® for the treatment of house dust mite allergy in young children
Read more
Post date
02/21/2025
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Read more
Post date
02/19/2025
Annual General Meeting in ALK-Abelló A/S on 13 March 2025
Read more
Post date
02/19/2025
Annual report 2024: ALK delivers 15% sales growth with profits up 65%
Read more